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ABSTRACT
Background Mitochondrial DNA (mtDNA) diseases are
rare disorders whose prevalence is estimated around 1 in
5000. Patients are usually tested only for deletions and
for common mutations of mtDNA which account for
5–40% of cases, depending on the study. However, the
prevalence of rare mtDNA mutations is not known.
Methods We analysed the whole mtDNA in a cohort
of 743 patients suspected of manifesting a mitochondrial
disease, after excluding deletions and common
mutations. Both heteroplasmic and homoplasmic variants
were identiﬁed using two complementary strategies
(Surveyor and MitoChip). Multiple correspondence
analyses followed by hierarchical ascendant cluster
process were used to explore relationships between
clinical spectrum, age at onset and localisation of
mutations.
Results 7.4% of deleterious mutations and 22.4% of
novel putative mutations were identiﬁed. Pathogenic
heteroplasmic mutations were more frequent than
homoplasmic mutations (4.6% vs 2.8%). Patients
carrying deleterious mutations showed symptoms before
16 years of age in 67% of cases. Early onset disease
(<1 year) was signiﬁcantly associated with mutations in
protein coding genes (mainly in complex I) while late
onset disorders (>16 years) were associated with
mutations in tRNA genes. MTND5 and MTND6 genes
were identiﬁed as ‘hotspots’ of mutations, with Leigh
syndrome accounting for the large majority of associated
phenotypes.
Conclusions Rare mitochondrial DNA mutations
probably account for more than 7.4% of patients with
respiratory chain deﬁciency. This study shows that a
comprehensive analysis of mtDNA is essential, and
should include young children, for an accurate diagnosis
that is now accessible with the development of next
generation sequencing technology.
INTRODUCTION
Since the ﬁrst identiﬁcation of mitochondrial DNA
(mtDNA) defects responsible for human diseases in
1988, it has been increasingly clear that mutations
in the mtDNA represent an important cause of
neuromuscular disorders.1 2 Nevertheless, today,
the prevalence of mtDNA disease is still difﬁcult to
assess for two main reasons.3 First, large series are
extremely rare because of clinical heterogeneity and
diagnosis complexity.4 Second, molecular screening
is usually restricted to detection of mtDNA dele-
tions and a few common mutations without having
accurate data on the prevalence of rare mutations.
Improvements in diagnosis methods led us to
study a large cohort of patients from the French
Mitochondrial Disease Network, including both
children and adults suspected of manifesting a
mitochondrial disorder. In our cohort, deletions
and common mutations of mtDNA had already
been excluded and we performed a comprehensive
analysis of the mitochondrial genome in order to
answer a number of key questions.
▸ What is the prevalence of rare mtDNA muta-
tions in mitochondrial disorders?
▸ What are the phenotypes associated with these
mutations?
▸ Is a comprehensive screening of mtDNA essen-
tial for optimal diagnostic approach?
PATIENTS AND METHODS
Study population
Over a 3 year period, 743 individuals suspected
of having a mitochondrial disorder were included
in the study. All were studied in French referral
centres by hospital specialists. A standardised chart
including clinical symptoms, imaging and extensive
laboratory work was completed for all patients (ie,
familial and clinical history, clinical presentation,
brain MRI, metabolic screening, mitochondrial
enzymes studies, histological and molecular ana-
lyses). Age of onset of clinical symptoms ranged
from the neonatal period to 74 years of age. The
patient population was based on the following
inclusion criteria: (1) clinical features suggesting
respiratory chain (RC) dysfunction and/or
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(2) metabolic screening suggesting RC dysfunction and/or
(3) isolated or multiple RC complex deﬁciency and/or (4) histo-
chemical evidence of mitochondrial abnormality in the
muscle biopsy and (5) exclusion of mtDNA deletion(s) and
m.3243A>G, m.8344A>G and m.8993T>C/G point muta-
tions. Affected individuals presenting with mtDNA depletion or
clear mendelian family history were also excluded. Among the
743 patients, 73 satisﬁed one, 301 two, 275 three and 94 four
inclusion criteria. Patients were subdivided into three groups
according to their age at presentation: <12 months of age,
1–16 years of age and >16 years of age.
Blood and tissue samples were obtained after parents of
affected children and adult patients had given informed consent.
Authorisations for individual data protection were obtained.
OXPHOS spectrophotometric measurements
Spectrophotometric studies of oxidative phosphorylation
(OXPHOS) complexes and citrate synthase were performed on
tissue homogenates and ﬁbroblasts, as previously described.5
Surveyor and MitoChip analysis
The entire human mtDNA was ﬁrst analysed by the Surveyor
method, as previously described.6 7 Then, screening was per-
formed with a resequencing chip (MitoChip, GeneChip
Mitochondrial Resequencing Array 2.0) according to the manu-
facturer’s instructions (Affymetrix, Inc).8 A custom bioinformat-
ics pipeline was then used for MitoChip analysis, as previously
described.9 Sequences were compared with the human mtDNA
consensus sequence, Genbank No J01415.2.10
Variants reported in the MITOMAP database (http://www.
mitomap.org/MITOMAP) as polymorphisms and present four
times or more in the mtDB database (http://www.mtdb.igp.uu.
se/) were considered as non-deleterious and excluded from
the study.
Statistical analysis
Variables
The variables used refer to clinical data of patients, age at onset
(<1 year, 1–16 years, >16 years) and mutation localisation
(tRNA genes vs protein coding genes).
Descriptive statistics
Descriptive statistics were used to characterise the population.
The unit of analysis was the patient and the analyses were done
on the entire population. All variables were categorical.
Multiple correspondence analysis and hierarchical ascendant
classiﬁcation
Analyses were performed on the patient population carrying
pathogenic mutations. The unit of analysis was the patient. To
explore the genotype–phenotype relationships, we ﬁrst used
multiple correspondence analysis (MCA)11 and next considered
the coordinates of the observations on the retained factorial
axes as new variables used for hierarchical ascendant classiﬁca-
tion (HAC).12 MCA allows a graphical representation of the
strength of the association between categories of selected vari-
ables. The points corresponding to the categories of each vari-
able (eg, age of onset of disease in three categories) are plotted
at distances from the origin that are inversely related to the
number of patients in a given category. Benzecri’s method was
used to select the number of axes considered in the analyses.13
MCA was built using age at onset and mutation localisation as
supplementary (non-active) variables as they were the variables
to explain. The variables with a low frequency (<15%) were
excluded from the analysis and Cramer’s V test was performed
to identify the variables strongly associated with others, which
were analysed as non-active variables. To build homogeneous
clusters of patients, we performed HAC based on the Ward
method. The clustering process was plotted as a dendrogram,
with horizontal branches representing the combination of
two clusters and vertical branches the degree of dissimilarity
between combined clusters. Long distances of the vertical seg-
ments indicated large differences between the clusters.
Associations between proﬁles of patients and variables used in
the model were tested with Fisher’s exact test. Test values were
calculated to measure the association between supplementary
variables and proﬁles of patients. We did not use other cluster-
ing methods, such as K means or latent class analysis, because of
the small size of the population. We chose hierarchical clustering
because of the small datasets and the absence of previous
assumptions about the number of clusters. All statistical analyses
were performed with SAS V.9.3 software (SAS Institute, Cary,
North Carolina, USA). A two tailed p≤0.05 was considered stat-
istically signiﬁcant.
RESULTS
The 743 patients were subdivided into 395 men and 348
women (ratio 1.13 : 1) with an average age of 25 years at the
time of the study. Clinical data are shown in the online
supplementary table S1 for the entire population, and depend-
ing on age of onset. Early clinical symptoms were seen during
the ﬁrst year of life for 356 (48%) patients, between 1 year and
16 years for 192 (25.8%) patients and in adulthood for
the remaining 180 (24.2%) patients. In 15 (2%) of 743 cases,
age of onset was unknown. Neurological presentations were the
most frequent (72.7% of total population). Before 1 year, the
most common symptom was psychomotor retardation (55.6%)
whereas cerebellar ataxia was commonly seen after 1 year of age
or during adulthood (37% and 25%, respectively). Epilepsy and
myoclonies were also very common (32.2%) whatever the age
of presentation. Muscular involvement was among the second
rank of clinical disorders, with chronic progressive external
opthalmoplegia (CPEO) mainly seen during childhood and
adulthood (27.1% and 32.2%, respectively). Postnatal growth
failure was highly represented before 1 year (29.5%).
Hypertrophic cardiomyopathy, and liver and kidney deﬁciencies,
were also mainly associated with onset before 1 year (11%,
27.8% and 11.5%, respectively). Optic atrophy was most fre-
quent when the disorder started during childhood (11.5%)
whereas peripheral neuropathy was present in 24.4% of patients
with adult onset. Paraclinical investigations are presented in the
online supplementary table S2. Brain MRI was abnormal in
82.1% of cases before 1 year of age, with a diagnosis of Leigh
or Leigh-like syndrome in 43.1% of patients. In patients with
adult onset, white matter involvement was the most common
pattern (43.8%) whereas posterior fossa atrophy/hypoplasia
was the most frequent when onset was during childhood
(29.5%). A lactate peak was detected in 60.6% of cases by
MRI spectroscopy, mainly in onset before 1 year (68.1%).
Hyperlactacidaemia was present in about 50% of patients but
hyperlactatorachia was the most common metabolic abnormality
(75.3%), mainly during childhood (83.3%) (see online supple-
mentary table S2). Results obtained from tissue biopsies, mainly
skeletal tissue, are presented in the online supplementary
table S3. The percentage of ragged red ﬁbres (RRF) and COX
negative ﬁbres increased with age of onset, reaching 48.9% and
56.9%, respectively, after 16 years of age. In muscle, the bio-
chemical activity of RC complexes was signiﬁcantly reduced in
Bannwarth S, et al. J Med Genet 2013;50:704–714. doi:10.1136/jmedgenet-2013-101604 705
Mutation report
59.4% of total biopsies. In liver tissue, a RC deﬁciency was seen
in 53.9% of cases before 1 year of age.
The presence of deletions and common point mutations
(m.3243A>G, m.8344A>G and m.8993T>C/G) of mtDNA
had previously been ruled out. The ﬁrst part of the study aimed
to search for heteroplasmic mutations by Surveyor analysis.
After eliminating the known polymorphisms (list available on
request) and, among new sequence variations, the 52 synonym-
ous variants and the 28 nucleotide substitutions in the D loop
region (list available on request), a total of 82 different hetero-
plasmic sequence variations corresponding to putative or known
pathogenic mutations were retained (see online supplementary
table S4).14–16 The 56 different variants corresponding to puta-
tive mutations were not reported in the MITOMAP database
and were present less than four times in the mtDB database.
Two variants only were found twice. The m.1938A>T variant
in MTRNR2 was found in a child who presented with psycho-
motor delay, epilepsy, ptosis, deafness and white matter lesions
on brain MRI. The second patient was an adult presenting
with epilepsy, cerebellar ataxia and stroke-like episodes.
Neuroimaging revealed patterns of Leigh/MELAS (mitochon-
drial encephalomyopathy, lactic acidosis and stroke-like epi-
sodes) overlap syndrome. In both cases, biochemical analysis
revealed no RC deﬁciency on muscle biopsy. The second
variant, m.13604G>C, was in the MTDN5 gene. The ﬁrst child
died at birth and presented a complex I (CI) deﬁciency in the
liver. The second child presented with myopathy, CPEO and
deafness. Muscle biopsy showed RRF and COX− ﬁbres but bio-
chemical analysis was not done.
Twenty-six different sequence variations were already known
as pathogenic mutations. The characteristics of the 34 corre-
sponding patients (34/743, 4.6%) are presented in table 1. Four
mutations (m.9185T>C, m.10191T>C, m.12706T>C and
m.13514A>G) were found in two patients, m.14487T>C in
three patients and m.13513G>A in four patients. Recurrent
mutations were responsible for Leigh syndrome in these
patients, except for one, and encoded subunits of CI, except the
m.9185T>C variant located in the MTATP6 gene (table 1). This
work expands the clinical spectrum of mtDNA disorders, with
the example of m.636A>G and m.12236G>A mutations that
had been previously reported in non-syndromic hearing loss and
that are associated with progressive multisystemic disorders in
our cohort.
In 74% of cases (25 of 34patients), symptoms started before
16 years of age (ﬁgure 1). When onset was before 1 year, all
patients presented a multisystemic disorder with abnormal brain
MRI, hyperlactataemia and elevation of the lactate to pyruvate
ratio. Leigh syndrome was found in 85% of cases (six of seven
patients), and usually associated with a CI deﬁciency in muscle
(four of six patients with muscle biopsy, 66.7%). When the
onset was between 1 and 16 years of age, ocular symptoms were
present in 44.4% of patients (8/18). In adult onset, cerebellar
ataxia was found in 44.4% of cases (four of nine patients) and
biochemical analysis identiﬁed a multiple RC deﬁciency in
muscle in 42.9% (three of seven patients with muscle biopsy).
In agreement with the mitochondrial enzyme data, mutations
were mainly located in CI genes before 1 year (ﬁve of seven
patients, 71.4%) and in tRNA genes in adult onset (six of nine
patients, 66.7%) (ﬁgure 1). Statistical analysis conﬁrmed these
results. MCA, used as a step of data reduction, retained 12
active variables: affected maternal relatives, psychomotor retard-
ation, regression, hypotonia, stroke-like episodes, epilepsy,
movement disorders, CPEO, optic atrophy, deafness, postnatal
growth retardation and Leigh syndrome. The following variables
were strongly correlated with others and were added as non-
active: cerebellar ataxia, white matter involvement and posterior
fossa atrophy or hypoplasia. HAC results showed three distinct
proﬁles (ﬁgure 1). The ﬁrst proﬁle of patients was associated
with early onset disease (<1 year) and mutations in protein
coding genes. The following variables were overrepresented in
this group of patients (p<0.05): psychomotor retardation,
hypotonia, optic atrophy, postnatal growth retardation and
Leigh syndrome. The second proﬁle of patients was associated
with late onset (>16 years) and mutations in tRNA genes. In
this proﬁle, affected maternal relatives were common (36%)
(p=0.13). We did not ﬁnd any association for the last proﬁle
of patients with a disease onset during childhood (1–16 years).
A dendrogram for cluster model is illustrated in the online
supplementary ﬁgure S1.
The second part of the study was to identify homoplasmic
mutations using MitoChip analysis in patients without patho-
genic heteroplasmic variants. Known polymorphisms and 180
novel variants (140 synonymous and 40 in the D loop) were
excluded (list available on request). The online supplementary
table S5 shows the 120 different homoplasmic variants found in
131 patients, which correspond to potential and deleterious
mutations. Among the 104 variants corresponding to putative
pathogenic mutations, four were present more than once (see
online supplementary table S5). The m.3228_3229 insA variant
in MTRN2 was found in two adults with a mitochondrial myop-
athy and in one child with Leigh syndrome. The m.8654T>C
(p.Ile43Thr) variant in MTATP6 was associated with exercise
intolerance and multiple RC deﬁciency in muscle of an adult
patient. The second affected individual was a child with Leigh
syndrome. None showed complex V deﬁciency. The last two
variants were in MTCYB. Two adult patients, presenting with
exercise intolerance, carried the m.15122A>G (p.Thr126Ala)
variant with classical mitochondrial features on muscle biopsy
and CIII deﬁciency in only one of two. The m.15774T>C
(p.Val343Ala) variant was associated with two early onset pre-
sentations (<1 year). The ﬁrst child presented with Toni Debré
Fanconi syndrome and the second one had a neurological pres-
entation (psychomotor delay, hypotonia and epilepsy). In both
cases, RRF ﬁbres were observed on muscle biopsy but we found
no RC deﬁciency.
Sixteen different sequence variations were already known
as pathogenic mutations and the characteristics of the 21 corre-
sponding patients (2.8%) are presented in table 2. The
m.1555A>G mutation, only seen in a homoplasmic state, was
present in three patients with a multisystemic disorder; only one
was deaf. Two other mutations were present more than once,
and both had been previously found in our study in the hetero-
plasmic state (m.4317delA, m.13513G>A).
Ocular involvement was observed in two-thirds of patients
and deafness in half of affected individuals during childhood
(ﬁgure 2). However, the population size was too small to
perform statistical studies.
Analysis of all (hetero- and homoplasmic) deleterious muta-
tions conﬁrmed the role of rare mtDNA mutations in paediatric
presentations (onset <16 years for 37 of 55 patients, 67.3%)
(ﬁgure 3). Neuromuscular symptoms were clearly predominant
in the 55 patients carrying pathogenic mutations. Liver failure
was associated with onset before 1 year, ocular involvement was
present in 50% of patients (12/24) in childhood presentations
and diabetes mellitus and deafness were found in 20.8% of
cases in adult onset disorders (5 of 24 patients). Statistical
analysis conﬁrmed previous ﬁndings. The same active and non-
active variables were retained by MCA. Results of HAC on the
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Table 1 Characteristics of patients carrying pathogenic mutations identified by Surveyor analysis
Gene Mutation
Gender/age at onset
(years) Clinical symptoms Brain MRI Lactate L/P
OH-but/
Ac-Ac
Muscle
histology RC
MTTF m.636A>G M<1 CNS (En, R, ME), Mu (H, ptosis), GI, anaemia,
neutropenia
Leigh, WM, thalamic lesions, lactate peak ↑ (B, CSF) ↑ N N ↓CI (Mu)
MTTL1 m.3258T>C 1<M<16 CNS (A, R, ME), HCM, Mu (SM) N ↑ (B, CSF,
U)
↑ ↑ N ↓CI+IV (Mu)
MTND1 m.3460G>A F > 16 CNS (E, A, MD) Cerebral atrophy ND ND ND N ND
MTT1 m.4317A>G M > 16 CNS (A, My, PS) Leigh-like, WM, cerebellar atrophy ND ND ND N ↓CI (Mu)
m.4317 delA F > 16 CNS (S-l), Mu (ptosis), D WM, stroke-like ND ND ND RRF, COX− ↓CI (Mu)
MTTN m.5667G>A 1<M<16 Mu (ptosis) ND ND ND ND RRF, COX− N (Mu)
m.5728T>C 1<M<16 Mu (SM, ptosis) ND ND ND ND Lipidosis,RRF,
COX−
N (Mu)
MTTS1 m.7472insC F > 16 CNS (PaS), Mu (SM, myalgias), DM ND ND ND ND RRF, COX− N (Mu)
MTTK m.8362T>G F>16 CNS (A), D, DM, lipomas ND ND ND ND ND ND
MTATP6 m.8609_8610insC M<1 CNS (PMR, E, R, A, Dys), Mu (H), PN-G Cerebellar atrophy ↑ (B) ↑ ND ND ↓CV (Mu)
N (F)
MTATP6 m.9185T>C 1<F<16 CNS (PMR, R, A), Re, IU-G, PN-G, anaemia Leigh ↑ (B) ↑ N Lipidosis, RRF ↓CV (Mu)
1<M<16 CNS (PMR, A), PN Leigh, cerebellar atrophy ↑ (CSF) ↑ N N N (Mu)
N (F)
MTND3 m.10191T>C M<1 CNS (PMR, A, E, R, S-l, Dys), Mu (PEO), OA,
IU-G
Leigh, stroke-like, thalamus lesions, WM,
lactate peak
↑ (B, CSF) ↑ ND Lipidosis ↓CI (Mu)
MTND4 m.11778G>A 1<F<16 CNS (Dys, dementia, PS), OA, Mu (SM, ptosis) WM, cerebral atrophy ↑ (U) ND ND N ↓CI+III (Mu)
MTTS2 m.12236G>A F>16 CNS (A), PN, Mu (myalgias) ND ND ND ND N ↓CI+III+IV
(Mu)
↓CI+III+IV
(F)
m.12276G>A 1<F<16 Mu (SM, PEO), PR ND ↑ (B) ND ND RRF ND
MTTL2 m.12316G>A M>16 Mu (PEO), PN N ND ND ND Lipidosis,RRF,
COX−
↓CI+IV (Mu)
MTND5 m.12414delT 1<F<16 Mu (exercise intolerance) ND ND ND ND Lipidosis ↓CI (Mu)
m.12706T>C 1<M<16 CNS (PMR, E, A), OA, D, PN-G Leigh, stroke-like, cerebellar atrophy ND ND ND ND ↓CI (Mu)
N (F)
M>16 CNS (S-l, En) ND ND ND ND N ↓CI+III (Mu)
↓CI (F)
m.13513G>A F<1 CNS (PMR, S-l), Mu (H, ptosis), HCM, OA, D Leigh, stroke-like, ↑ (B) ↑ ↑ RRF ↓CI (Mu)
M<1 CNS (PMR, R, S-l, M-l H, B) PN, Mu (PEO) Leigh, stroke-like, WM ↑ (B, CSF) ↑ ↑ N ND
1<F<16 CNS (A, ME), cataract Re, D, PN-G Leigh cerebral atrophy ↑ (B) ↑ ND RRF N (Mu)
1<F<16 CNS (A), OA, PN-G Leigh, cerebellar atrophy ↑ (B) ND ND Lipidosis, RRF ↓CI (Mu)
m.13514A>G 1<M<16 Mu (ptosis), VA, leucopenia Leigh N ↑ N Lipidosis RRF N (Mu)
N (F)
F<1 CNS (PMR, A), Mu (H), L, PN-G Leigh ↑ (B, CSF) ↑ ↑ Lipidosis N (Mu)
N (L)
MTND6 m.14487T>C 1<F<16 CNS (PMR, S-l), Mu (PEO), PN-G Leigh ↑ (CSF) ↑ ↑ N N (Mu)
1<M<16 CNS (R, Dys, PS) Leigh, stroke-like ↑ (B) ↑ ND ND N (Mu)
N (F)
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55 patients showed three distinct proﬁles (ﬁgure 3). Early onset
disease and mutations in protein coding genes were associated
with a proﬁle of patients characterised by psychomotor retard-
ation, regression, stroke-like episodes, movement disorders,
Leigh syndrome and white matter involvement. Late onset was
associated with mutations in the tRNA genes. Affected maternal
relatives were also found predominantly in this second proﬁle
(33%), despite being non-signiﬁcantly associated (p = 0.18).
Again, we found no pattern associated with an onset during
childhood. A dendrogram for cluster model is illustrated in the
online supplementary ﬁgure S2.
DISCUSSION
In OXPHOS disorders, identiﬁcation of a causative mutation(s)
is critical to conﬁrm the diagnosis and to propose accurate
genetic counselling and prenatal diagnosis, but molecular ana-
lysis is problematic due to the large genetic heterogeneity of
mtDNA related disorders. Primary mtDNA defects include large
rearrangements and point mutations. In clinical practice, most
suspected patients do not have their entire mitochondrial
genome sequenced but are usually tested only for deletions and
a small number of common mutations. Several groups have
reported that testing for common mtDNA defects in adults with
suspected mitochondrial disease can have quite a high diagnostic
yield, ranging from 10% to 40% of patients tested.3 4 17 Testing
for common mtDNA mutations has a much lower diagnostic
yield in children, ranging from 2–4% to 25%.18 19 Recently,
looking for 10 mtDNA point mutations in 3168 neonatal cord
blood samples revealed that at least 1 in 200 healthy humans
harbours a pathogenic mtDNA mutation, although at low
mutant heteroplasmy.20 However, to date, the rate of rare muta-
tions is totally unknown. To answer this question, we analysed
the whole mitochondrial genome of 743 patients suspected of
manifesting a mitochondrial disease after excluding deletions
and the most common mutations.
A total of 55 patients (7.4%) harboured pathogenic mutations
responsible for an onset disorder before adulthood in 67% of
cases and before 1 year of age in 24% of cases. Previous studies
have suggested that 50% or more of all patients have adult
onset. However, in these studies, the most common mutations
(mainly deletions and m.3243A>G) that were mainly found
in adult presentations (CPEO, maternally inherited deafness
and diabetes (MIDD), etc) were not excluded. The French
Mitochondrial Disease Network includes approximately 90% of
patients investigated for mitochondrial disease in France. The
743 patients included in the study were doubly selected because
they were highly ‘suspect’ of RC disorder, and they did not
carry common mtDNA mutations. Our results suggest that in
the French population, the clinical presentations that are not
associated with common mutations begin mainly before adult-
hood. Further studies using next generation sequencing technol-
ogy will be necessary to conﬁrm this point.
Assuming that heteroplasmic and homoplasmic mutations
may have different effects, we also analysed both populations
separately. As expected, heteroplasmic mutations were more fre-
quent than homoplasmic mutations (4.6% vs 2.8%). Symptoms
appeared before the age of 16 years in 75% of patients carrying
heteroplasmic pathogenic mutations and in 58% of patients
carrying homoplasmic pathogenic mutations. If a number of
factors have led to an exaggerated perception that the mtDNA
genome is rarely involved in children affected by mitochondrial
disorders, our results show that rare mtDNA mutations are a
non-negligible cause of paediatric RC deﬁciency because 6.75%
Ta
bl
e
1
Co
nt
in
ue
d
G
en
e
M
ut
at
io
n
G
en
de
r/
ag
e
at
on
se
t
(y
ea
rs
)
Cl
in
ic
al
sy
m
pt
om
s
Br
ai
n
M
RI
La
ct
at
e
L/
P
O
H
-b
ut
/
A
c-
A
c
M
us
cl
e
hi
st
ol
og
y
RC
M
<
1
CN
S
(E
n,
E)
,M
u
(H
),
L
Le
ig
h,
th
al
am
ic
le
sio
ns
↑
(B
,C
SF
)
↑
↑
N
↓C
I(
M
u)
m
.1
45
35
_1
45
36
in
sC
M
>
16
DM
,D
N
D
N
D
N
D
N
D
N
D
↓C
I(
F)
M
TT
E
m
.1
47
10
G
>
A
1<
F<
16
CN
S
(M
-l
H)
,M
u
(P
EO
),
PR
N
D
N
D
N
D
N
D
Li
pi
do
sis
RR
F,
CO
X−
N
(M
u)
m
.1
47
24
G
>
A
1<
M
<
16
CN
S
(A
,M
y)
,M
u
(e
xe
rc
ise
in
to
le
ra
nc
e)
,R
e,
PR
,
D,
G
I,
DM
Le
uk
od
ys
tro
ph
y,
ce
re
br
al
at
ro
ph
y
↑
(B
)
N
D
N
D
RR
F
N
D
M
TC
YB
m
.1
56
99
G
>
C
1<
M
<
16
CN
S
(P
M
R,
A)
,M
u
(H
),
PN
,O
A
W
M
,c
er
eb
el
la
ra
tro
ph
y
↑
(B
,C
SF
)
↑
↑
RR
F
↓C
III
(F
)
N
(M
u)
M
TT
G
M
TN
D3
m
.1
00
10
T>
C
m
.1
01
91
T>
C
1<
M
<
16
CN
S
(D
ys
,P
M
R)
Le
ig
h,
ce
re
be
lla
ra
tro
ph
y
N
N
↑
N
↓C
I(
M
u)
↓C
I(
F)
Th
e
la
st
lin
e
on
th
e
ta
bl
e
co
rre
sp
on
ds
to
a
pa
tie
nt
w
ho
ca
rri
ed
tw
o
m
ut
at
io
ns
.
↓,
de
cr
ea
se
d;
↑,
in
cr
ea
se
d;
B,
bl
oo
d;
CI
,I
I,
III
,I
V,
V,
re
sp
ira
to
ry
ch
ai
n
co
m
pl
ex
es
;C
N
S,
ce
nt
ra
ln
er
vo
us
sy
st
em
(A
,c
er
eb
el
la
ra
ta
xi
a;
B,
bu
lb
ar
in
vo
lv
em
en
t;
CS
F,
ce
re
br
o
sp
in
al
flu
id
;D
ys
,d
ys
to
ni
a;
E,
ep
ile
ps
y;
En
,e
nc
ep
ha
lo
pa
th
y;
F,
fe
m
al
e;
M
,m
al
e;
M
D,
m
ov
em
en
t
di
so
rd
er
s,
M
E,
m
yo
cl
on
ic
ep
ile
ps
y;
M
-l
H,
m
ig
ra
in
e-
lik
e
he
ad
ac
he
s;
M
RI
,m
ag
ne
tic
re
so
na
nc
e
im
ag
in
g;
M
y,
m
yo
cl
on
ie
s;
PM
R,
ps
yc
ho
m
ot
or
re
ta
rd
at
io
n;
Pa
S,
pa
rk
in
so
ni
an
sy
nd
ro
m
e;
PS
,p
yr
am
id
al
sy
nd
ro
m
e;
R,
re
gr
es
sio
n;
S-
l,
st
ro
ke
-li
ke
ep
iso
de
);
CO
X−
,C
O
X
ne
ga
tiv
e
fib
re
s;
D,
de
af
ne
ss
;D
M
,d
ia
be
te
s
m
el
lit
us
;F
,f
ib
ro
bl
as
ts
;G
I,
ga
st
ro
in
te
st
in
al
di
so
rd
er
s;
HC
M
,h
yp
er
tro
ph
ic
ca
rd
io
m
yo
pa
th
y;
IU
-G
,i
nt
ra
ut
er
in
e
gr
ow
th
fa
ilu
re
;L
,l
iv
er
in
vo
lv
em
en
t;
L/
P,
la
ct
at
e/
py
ru
va
te
;M
u,
m
us
cl
e
(H
,h
yp
ot
on
ia
;P
EO
,p
ro
gr
es
siv
e
ex
te
rn
al
op
ht
ha
lm
op
le
gi
a;
SM
,s
ke
le
ta
lm
yo
pa
th
y)
;N
,n
or
m
al
;N
D,
no
t
de
te
rm
in
ed
;O
A,
op
tic
at
ro
ph
y;
O
H-
bu
t/A
c-
Ac
,h
yd
ro
xy
-b
ut
yr
at
e/
ac
et
o-
ac
et
at
e;
PN
,p
er
ip
he
ra
ln
eu
ro
pa
th
y;
PN
-G
,p
os
tn
at
al
gr
ow
th
fa
ilu
re
;
PR
,p
ig
m
en
ta
ry
re
tin
op
at
hy
;R
C,
re
sp
ira
to
ry
ch
ai
n;
Re
,r
en
al
in
vo
lv
em
en
t;
RR
F,
ra
gg
ed
re
d
fib
re
s;
U,
ur
in
e;
VA
,d
ec
re
as
ed
vi
su
al
ac
ui
ty
;W
M
,w
hi
te
m
at
te
r
in
vo
lv
em
en
t.
708 Bannwarth S, et al. J Med Genet 2013;50:704–714. doi:10.1136/jmedgenet-2013-101604
Mutation report
Figure 1 Analysis of the population harbouring heteroplasmic pathogenic mitochondrial DNA (mtDNA) mutations according to age at onset.
n, number of patients. (A) Age at onset (in years). (B) Clinical characteristics. CNS, central nervous system; D, deafness; DM, diabetes mellitus.
GR, growth retardation (intrauterine or postnatal); HCM, hypertrophic cardiomyopathy; L, liver involvement; Mu, muscle; OC, ocular involvement
(optic atrophy or pigmentary retinopathy); PN, peripheral neuropathy; Re, renal involvement. (C) Respiratory chain analysis by spectrophotometry.
CI, CV, respiratory chain deﬁciency in complex I, in complex V; mul, multiple respiratory chain deﬁciency; N, normal. (D) Localisation of mtDNA
mutations. CI, CIII, CV, genes encoding subunits of complexes I, III, V; tRNA, genes encoding tRNA. (E) Statistical analyses with hierarchical
ascendant classiﬁcation of pathogenic heteroplasmic mutations found in the 34 patients. The upper right quadrant is complementary to the bottom
left quadrant. The numbers on the axes are the scores that represent the contribution of each feature to the overall inertia. Our model (axes 1–3)
explains 48% of total inertia. The circles represent the variables. Their size is proportional to the quality of representation of the variables on the
plane (axes 1 and 3). Patients with disease onset <1 year are clustered with mutations in protein coding genes, psychomotor retardation, hypotonia,
optic atrophy, postnatal growth retardation and Leigh syndrome. Patients with disease onset >16 years are clustered with mutations in tRNA genes
and affected maternal relatives.
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of patients with onset before adulthood (37 of 548) carried rare
pathogenic mtDNA mutations.
One of the main results of this study was that the location of
mtDNA mutations inﬂuenced the age of onset of OXPHOS dis-
eases. We found a signiﬁcant correlation between mutations in
protein coding (mainly CI) genes and early onset disorder
(<1 year) on the one hand, and between mutations in tRNA
genes and adult onset on the other hand; the hierarchical clus-
tering allowing unambiguous class assignments of patients with
early and late onset disease. These results suggest that mutations
in tRNA genes are much better tolerated than those that directly
affect the functioning of CI whose defect is the most frequently
observed. It was previously thought that a mtDNA origin
accounted for only 5–10% of paediatric cases.21 However, a
recent study of 109 children with isolated CI deﬁciency identi-
ﬁed pathogenic mtDNA mutations in 29% of cases.22 In our
study, mutations in MTND genes were found in 11 of 75
patients (14.7%) with an isolated CI deﬁciency before the age
of 16 years but this percentage is likely underestimated because
other deleterious mutations were likely present among the 44
variants corresponding to putative mutations that we identiﬁed
in MTND genes. Among CI genes, MTND5 and MTND6 corre-
sponded to ‘hotspots’ for disease causing mutations, being,
respectively, found mutated in 11 (20%) and seven (12.7%) of
55 patients , with Leigh syndrome accounting for the large
majority of associated phenotypes.
A total of 167 patients (22.4%) harboured putative patho-
genic mutations, with homoplasmic novel variants being
more frequent than heteroplasmic variants (14.6% vs 7.8%).
Interpretation of the clinical signiﬁcance of rare variants is chal-
lenging due to the highly polymorphic nature of mtDNA. The
existing scoring systems to evaluate the pathogenicity of a
mtDNA variant consider several parameters, including single
ﬁbre PCR or cybrid studies, multiple family reports, segregation
within the family, measurable biochemical defect, evolutionary
conservation, etc.23 24 Collection of data and tools to perform
functional studies is in progress but we currently do not have
the information needed to precisely deﬁne the status of the 160
different variants identiﬁed. Nevertheless, 32 patients (4.3%)
carried novel variants in protein coding genes with high or
medium amino acid conservation and a damaging and not toler-
ated status according to our in silico analysis using PolyPhen 2
Table 2 Characteristics of patients with pathogenic mutations identified by MitoChip analysis
Gene Mutation
Gender/age at
onset Clinical symptoms Brain MRI Lactate L/P
OH-but/
Ac-Ac Muscle histology RC
MTRNR1 m.1555A>G 1<F<16 CNS (dementia), Mu (SM),
HCM, D
WM ND ND ND RRF, COX−,
lipidosis
N (Mu)
M<1 CNS (PMR), Mu (SM, H), IU-G,
PN-G
N ND ↑ ND ND ↓CI, CIII, CIV,
CV (Mu, F)
1<M<16 OA, PN, PN-G Cerebellar atrophy ND N ND ND N (Mu)
MTTV m.1644G>A M>16 CNS (E, S-l, dementia) Cerebral atrophy ND ND ND COX− ↓CIV (Mu)
MTTL1 m.3303C>T M<1 Mu (H), HCM, L N ↑(B) ↑ N Lipidosis ↓CI+III (Mu)
N (F)
MTND1 m.3395A>G F>16 Mu (SM, myalgia, ptosis), HCM,
D, DM
ND ND ND ND COX− N (F)
m.3460A>G M>16 CNS (A), PN, Mu (ptosis), HCM,
L, OA
Leigh ND N ND RRF, COX−,
lipidosis
↓CI (Mu)
m.3890G>A M<1 CNS (PMR, E, A), Mu (PEO), L,
OA
Leigh, thalamus lesions ↑ (B, CSF) ↑ ND Lipidosis N (Mu)
↓CI, CIII, CIV
(F)
MTTI m.4300A>G F>16 HCM ND ND ND ND COX−, lipidosis ND
m.4316A>G F> 16 Mu (SM, PEO) ND ND ND ND RRF, COX− ↓CIII+IV (Mu)
m.4317 delA M<1 CNS (PMR, En, R, E) N ND ND ND Lipidosis ↓CIV (Mu)
M>16 Mu (ptosis) ND ND ND ND RRF, COX− ↓CIII (Mu)
MTTW m.5521G>A F>16 CNS (PMR, A, E, MD, S-l), Mu
(SM), eating disorder
Leukodystrophy,
cerebellar atrophy
↑ (B) ↑ N RRF, COX−,
lipidosis
↓CI, CIV, ↓CII
+III, CIII (Mu)
m.5540G>A M>16 CNS (A, dementia), Mu (SM), D N ND ND ND RRF, COX−,
lipidosis
↓CIV (Mu)
MTATP6 m.9185T>C F>16 CNS (A) ND ND ND ND N N (Mu)
MTND5 m.13513G>A 1<M<16 CNS (En, E, M-lH), PN, Mu
(SM), HCM, PR, OA, D
Cerebellar atrophy,
stroke-like
ND ↑ ND Mitochondrial
proliferation
↓CI (Mu)
1<M<16 CNS (PMR, A), Mu (PEO), OA,
IU-G, PN-G
ND ND ND ND ND ND
MTND6 m.14459G>A F<1 CNS (R) Leigh N (B) ND ND ND N (Mu), ↓CI (L),
↓CI+IV (F)
M<1 CNS (PMR, Dys), Mu (ptosis) Leigh ↑ (B, CSF) ND ND ND ↓CI (Mu, F)
m.14487T>C 1<M<16 CNS (PMR, S-l, PS), Mu (ptosis) Leigh ↑ (CSF) N N N ↓CI (Mu)
MTCYB m.15234G>A 1<M<16 CNS (R, PMR, E, S-l, M-lH), Mu
(PEO, SM), D, cataract
Leigh, Stroke-like,
leukodystrophy,
↑ (B, CSF) ↑ ↑ RRF ↓CI, CIII, CIV
(M), N (F)
↓, decreased; ↑, increased; B, blood; CI, II, III, IV, V, respiratory chain complexes; CNS, central nervous system (A, cerebellar ataxia; Dys, dystonia; E, epilepsy; En, encephalopathy;
MD, movement disorders, M-l H, migraine-like headaches; PMR, psychomotor retardation; PS, pyramidal syndrome; R, regression; S-l, stroke-like episode); COX−, COX negative fibres;
D, deafness; DM, diabetes mellitus; F, fibroblasts; HCM, hypertrophic cardiomyopathy; IU-G, intrauterine growth failure; L, liver involvement; L/P, lactate/pyruvate; Mu, muscle (H,
hypotonia; PEO, progressive external ophthalmoplegia; SM, skeletal myopathy); N, normal; ND, not determined; OA, optic atrophy; OH-but/Ac-Ac, hydroxy-butyrate/aceto-acetate;
PN, peripheral neuropathy; PN-G, postnatal growth failure; PR, pigmentary retinopathy; RC, respiratory chain; RRF, ragged red fibres; WM, white matter involvement.
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and SIFT, respectively (see online supplementary tables S4
and S5).25 In 15 of 32 patients , the identiﬁed variant was corre-
lated with a corresponding biochemical defect (not shown).
Regarding tRNA coding genes, mutations were detected in
18 of 22 genes and were found spread all over the structural
domains of the corresponding tRNAs. Seventeen of the 36
newly detected variants affect highly conserved nucleotides
(table 3). Despite the fact that conservation is often poor in
picking pathogenicity,28 29 this is a criterion that may be taken
into account to prioritise future functional studies allowing
assessment of tRNA variants using scoring systems.
In conclusion, we have reported the ﬁrst study to determine
the prevalence of rare mtDNA mutations in RC disorders.
Although further analyses are needed to deﬁne precisely the
pathogenic or polymorphic nature of all of the novel variants
identiﬁed, our results show that rare mtDNA mutations
account for more 7.4% of patients with mitochondrial disor-
ders. Careful selection of the population studied and the
choice of tissues concerned by molecular analysis, which was
carried out mainly in muscle (88% of cases), may explain this
mutation rate, probably higher if one takes into account some
new variants are probably deleterious. In this cohort of
patients, we excluded those carrying a deletion or common
mtDNA mutations. It is interesting to note that within the
French Mitochondrial Disease Network, we have a rate of
8% for these common abnormalities of the mitochondrial
Figure 2 Analysis of the population harbouring homoplasmic pathogenic mitochondrial DNA (mtDNA) mutations according to age at onset.
n, number of patients. (A) Age at onset (in years). (B) Clinical characteristics. CNS, central nervous system; D, deafness; DM, diabetes mellitus;
GR, growth retardation (intrauterine or postnatal); HCM, hypertrophic cardiomyopathy; L, liver involvement; Mu, muscle; OC, ocular involvement
(optic atrophy or pigmentary retinopathy); PN, peripheral neuropathy; Re, renal involvement. (C) Respiratory chain analysis by spectrophotometry.
CI, CIII, CIV, respiratory chain deﬁciency in complex I, complex III, complex IV; mul, multiple respiratory chain deﬁciency; N, normal. (D) Localisation
of mtDNA mutations. CI, CIII, CV, genes encoding subunits of complexes I, III, V; rRNA, genes encoding rRNA; tRNA, genes encoding tRNA.
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Figure 3 Analysis of the pooled populations harbouring heteroplasmic or homoplasmic pathogenic mitochondrial DNA (mtDNA) mutations
according to age at onset. n, number of patients. (A). Age at onset (in years). (B) Clinical characteristics. CNS, central nervous system; D, deafness;
DM, diabetes mellitus; GR, growth retardation (intrauterine or postnatal); HCM, hypertrophic cardiomyopathy; L, liver involvement; Mu, muscle; OC,
ocular involvement (optic atrophy or pigmentary retinopathy); PN, peripheral neuropathy; Re, renal involvement. (C) Respiratory chain analysis by
spectrophotometry. CI, CIII, CIV, CV, respiratory chain deﬁciency in complex I, complex III, complex IV, complex V; mul, multiple respiratory chain
deﬁciency; N, normal. (D) Localisation of mtDNA mutations. CI, CIII, CV, genes encoding subunits of complexes I, III, V; rRNA, genes encoding rRNA;
tRNA, genes encoding tRNA. (E). Statistical analyses with hierarchical ascendant classiﬁcation of pathogenic mutations found in the 55 patients. Our
model (axes 1–3) explains 45% of total inertia. The circles represent the variables. Their size is proportional to the quality of representation of the
variables on the plane (axes 1 and 2). Patients with disease onset <1 year are clustered with protein coding gene mutations, psychomotor
retardation, stroke-like episodes, regression, movement disorders, Leigh syndrome and white matter involvement. Patients with late onset are
clustered with tRNA gene mutations and affected maternal relatives.
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genome. The sum of the rates obtained in our network for
both common and rare mutations shows how the complete
screening of mtDNA is essential. It should be performed for
an optimal diagnosis, including in young children, and will
now be accessible with the development of next generation
sequencing technology that provides a one step approach in
detecting common and uncommon point mutations, as well as
deletions.
Table 3 Novel variants in tRNA genes and tentative prediction of impact according to the level of nucleotide conservation of the affected
position
Gene
Sequence
variation
Gene
reading
Structural domains in
tRNA
Position in
tRNA
Change in
tRNA
Nucleotide
conservation Tentative prediction
MTTF m.579T>C Direct Acc stem 3 T>C 90%<x<100%, Y or R Possibly pathological
m.592C>T Direct D loop 16 C>T <50% Polymorphism
m.593T>C Direct D loop 17 T>C <50% Polymorphism
m.645A>G Direct Acc stem 71 A>G 90%<x<100%, all R Possibly pathological
MTTV m.1628C>T Direct Anticd stem 29 C>T <50% Polymorphism
m.1645A>G Direct Variable region 46 A>G 100%A Possibly pathological
MTTL1 m.3258T>C Direct Anticd stem 27 T>C 90%<x<100%, all R Possibly pathological
MTTQ m.4354C>T Inverse Variable region 48 G>A <50% Polymorphism
m.4394C>A Inverse Acc stem 7 G>T <50% Polymorphism
MTTM m.4449G>A Direct T stem 52 G>A 100%G Possibly pathological
MTTW m.5527A>G Direct D loop 16 A>G 50%<x<90%, Y or R Probable
polymorphism
m.5542C>T Direct Anticd loop 32 C>T 100%C Possibly pathological
m.5560G>A Direct T stem 51 G>A 50%<x<90%, all R Probable
polymorphism
m.5574T>C Direct Acc stem 68 T>C 50%<x<90%, all Y Probable
polymorphism
MTTA m.5605A>G Inverse T loop 55 T>C 90%<x<100%, Y or R Possibly pathological
m.5608C>T Inverse T stem 52 G>A 50%<x<90%, all R Probable
polymorphism
MTTN m.5663C>T Inverse Acc stem 67 G>A 50%<x<90%, all R Probable
polymorphism
m.5690A>G Inverse Anticd stem 40 T>C 100%T Possibly pathological
MTTC m.5793A>G Inverse T loop 60 T>C <50% Polymorphism
m.5800A>G Inverse Anticd loop 32 T>C 90%<x<100%, all Y Possibly pathological
MTTY m.5865T>C Inverse Anticd stem 31 A>G 90%<x<100%, all R Possibly pathological
MTTS1 m.7455A>G Inverse T stem 64 T>C 90%<x<100%, all Y Possibly pathological
MTTD m.7567C>T Direct T loop 54 C>T 50%<x<90%, Y or R Probable
polymorphism
MTTK m.8306T>C Direct D-stem 12 T>C 100%T Possibly pathological
MTTH m.12168G>A Direct Anticd loop 34 G>A 100%G Possibly pathological*
m.12173T>C Direct Anticd stem 39 T>C 50%<x<90%, Y or R Probable
polymorphism
m.12174C>T Direct Anticd stem 40 C>T 90%<x<100%, all Y Possibly pathological
m.12197_12198InsC Direct T stem 64–65 Ins C / Probable
polymorphism
MTTL2 m.12324C>T Direct T stem 61 C>T 100%C Possibly pathological
MTTE m.14697C>T Inverse T stem 50 G>A 50%<x<90%, Y or R Probable
polymorphism
MTTT m.15916T>C Direct Anticd stem 31 T>C 50%<x<90%, all Y Probable
polymorphism
m.15926C>T Direct Anticd stem 41 T>C 90%<x<100%, all Y Possibly pathological
m.15936A>T Direct T stem 52 A>T 50%<x<90%, Y or R Probable
polymorphism
m.15947A>G Direct Acc stem 67 A>G 50%<x<90%, Y or R Probable
polymorphism
MTTP m.15977C>T Inverse T stem 50 G>A 50%<x<90%, all R Probable
polymorphism
m.15992A>T Inverse Anticd loop 34 T>A 100%T Possibly pathological*
Nucleotide conservations are retrieved from the compilation of tRNA genes of each specificity taking into account 150 mammalian mitochondrial genomes (http://mamit-trna.u-strasbg.
fr/).26 27 Four levels of conservation are considered. Whenever a nucleotide is conserved in more than 90% of the sequences, the tentative prediction is that the probability of having a
structural or functional role is high. Its mutation may thus possibly have pathological consequences. Possible pathological variants are shown in italic.
*Position 34 corresponds to the first nucleotide of the tRNA anticodon triplet. The mutations concerning both MTTH and MTTP do not affect the codon reading. However, they may
affect the efficiency of aminoacylation or of post-transcriptional modification, leading to less efficient translation.
Acc stem, acceptor stem; Anticd loop, anticodon loop; Anticd stem, anticodon stem; R, purine base; Y, pyrimidic base.
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